ZIOPHARM Oncology, Inc. (ZIOP) Reports In-Line Q1 Loss

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on ZIOPHARM Oncology, Inc. (ZIOP) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• Plexus Corp (PLXS) Tops Q2 EPS by 7c
• Amerant Bancorp Inc. (AMTB) Misses Q1 EPS by 5c